CD274 and non-small cell lung carcinoma: However, our finding is in line with data from an earlier study in which, after 6 months of treatment, five out of five NSCLC patients with progressive disease or death had PD-L1+ CTCs, whereas none of the responding patients harbored PD-L1+ CTCs (n = 5, SD and PR) [36].